← Leaderboards
Kerry Anne Rogers
Ohio State University
$1,321,382
Attributed
$2,642,763
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $538.2K · FY2021–25$1M$750K$500K$250K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,642,763 · 1
By mechanism
R01$2,642,763 · 1
Top collaborators
- Jennifer A. Woyach5 shared
Most similar at Ohio State University
Same institution · by research overlap
- Jennifer A. Woyach$6,733,332
- Michael R Grever$17,739,693
- Susheela Tridandapani$6,556,394
- Amy Jo Johnson$2,112,180
- Lapo Alinari$4,506,413
Others in their field
Other Emerging Leaders on “Economics”
- Joel A Lipkin · Four Points Technology, Llc$184,504,844
- Terry Drinkwine · Carahsoft Technology Corporation$93,741,163
- Peter W Pisters · University Of Tx Md Anderson Can Ctr$44,099,853
- Christopher Barnaby Nelson · University Of Melbourne$27,954,628
- Priyamvada Acharya · Duke University$22,454,410
- Barbara Halina Braffett · George Washington University$17,931,151
Research focus
EconomicsAdult LeukemiaAgammaglobulinaemia Tyrosine KinaseDisease RemissionAntibody TherapyAntibodiesBcl3 GeneAntibody-Dependent Cell CytotoxicityAntibody-Dependent EnhancementBiological FactorsBlocking AntibodiesCell PhysiologyCellsCharacteristicsChronic Lymphocytic LeukemiaChronic Lymphocytic Leukemia CellClinical DevelopmentBehaviorClinical TrialsBiochemicalCombined Modality TherapyCurative TreatmentsDesignEffector Cell
Grant awards (5)
Targeted Therapies for Lymphoid Malignancies$538,241
R01 · FY2025 · CA
Targeted Therapies for Lymphoid Malignancies$511,329
R01 · FY2024 · CA
Targeted Therapies for Lymphoid Malignancies$527,476
R01 · FY2023 · CA
Targeted Therapies for Lymphoid Malignancies$527,476
R01 · FY2022 · CA
Targeted Therapies for Lymphoid Malignancies$538,241
R01 · FY2021 · CA